☆ 4.4 Article

Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma

INTERNATIONAL UROLOGY AND NEPHROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma

Tomoya Mizuno et al.

Summary: The study found that in UTUC patients, the expression of B7-H4 in the tumor microenvironment is related to tumor progression, response to chemotherapy, and overall survival. The expression of CD8 and TIA-1 also influences patient response to chemotherapy and survival.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02

Andrea Necchi et al.

Summary: The study found that single-agent neoadjuvant pembrolizumab did not appear to be a promising treatment strategy for patients with biomarker-unselected, high-risk localized UTUC.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Add to Collection

Article Immunology

B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling

Sadiye Amcaoglu Rieder et al.

Summary: B7-H7 induced transcriptomic changes are insufficient to support full costimulation with TCR signaling, inhibiting T-cell activation and proliferation in the presence of TCR and CD28 signaling.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Review Urology & Nephrology

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update

Morgan Roupret et al.

Summary: The updated EAU guidelines on UTUC aim to assist clinicians in evidence-based management, providing recommendations on diagnosis, risk stratification, radical and conservative treatment, and prognostic factors. Due to the rarity of UTUC, there is insufficient data to provide strong recommendations. Recommendations are based on the 2017 TNM classification and emphasize individualized treatment based on proposed risk stratification.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival

Takao Kamai et al.

Summary: In patients with metastatic RCC, high expression of A2AR in primary tumors was associated with metastatic profiles. Patients treated with anti-PD-1 antibody or a combination of anti-PD-1 and anti-CTLA4 antibodies, or anti-VEGF agents showed better response and longer overall survival if the primary tumor had higher PD-L1 expression and lower A2AR expression.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment

Nadia Bolandi et al.

Summary: Gastric cancer is the third leading cause of death globally, despite a stable reduction in its incidence. Poor response to common treatments and late diagnosis make it a lethal cancer. The emerging use of immunotherapy and immune checkpoint inhibitors has changed the landscape of treatment for gastric cancer patients, with the manipulation of signals from the B7 family showing significant potential in management.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory for Pathway to PD1

Rupal S. Bhatt et al.

Summary: The study identified KIR3DL3 as an inhibitory receptor for HHLA2, suggesting that blocking both PD1 and KIR3DL3 pathways may be a more effective way to reverse tumor immune evasion.

CANCER IMMUNOLOGY RESEARCH (2021)

Add to Collection

Article Oncology

Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study)

Sida Cheng et al.

Summary: sTIL serves as a prognostic biomarker in locally advanced UTUC, with high sTIL density positively correlated with the expression levels of PD-1/PD-L1/CD8 axis. Exposure to aristolochic acid (AA) was associated with increased sTIL and elevated PD-L1 expression, suggesting AA-related UTUC might be a distinct subgroup with unique tumor microenvironment characteristics.

ONCOIMMUNOLOGY (2021)

Add to Collection

Article Cell Biology

HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer

Li Wei et al.

HUMAN CELL (2020)

Add to Collection

Article Oncology

Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density

Akinori Nukui et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Add to Collection

Article Pathology

The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder

Julio Calvete et al.

HUMAN PATHOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics

Ellen Pure et al.

ONCOGENE (2018)

Add to Collection

Article

The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis

Masataka Shimonosono et al.

Oncotarget (2018)

Add to Collection

Article Multidisciplinary Sciences

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure

Ankur Chakravarthy et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Review Oncology

High Neutrophil-to-lymphocyte Ratio as Prognostic Factor in Patients Affected by Upper Tract Urothelial Cancer: A Systematic Review and Meta-analysis

Michele Marchioni et al.

CLINICAL GENITOURINARY CANCER (2017)

Add to Collection

Review Oncology

The biology and function of fibroblasts in cancer

Raghu Kalluri

NATURE REVIEWS CANCER (2016)

Add to Collection

Article Oncology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Suzanne L. Topalian et al.

CANCER CELL (2015)

Add to Collection

Editorial Material Oncology

A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2

Yanping Xiao et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Editorial Material Oncology

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Murali Janakiram et al.

ONCOIMMUNOLOGY (2015)

Add to Collection

Review Oncology

Cancer-related inflammation and treatment effectiveness

Connie I. Diakos et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Multidisciplinary Sciences

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

Ruihua Zhao et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection

Article Medicine, General & Internal

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

Add to Collection

Review Biochemistry & Molecular Biology

Hallmarks of Cancer: The Next Generation

Douglas Hanahan et al.

CELL (2011)

Add to Collection

Review Immunology

Inhibitory B7-family molecules in the tumour microenvironment

Weiping Zou et al.

NATURE REVIEWS IMMUNOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.